JPM vs NMAI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
NMAI presents a stark contradiction between its deterministic health markers and its value profile. The Piotroski F-Score of 1/9 indicates severe fundamental weakness by corporate standards, which heavily weighs down the health assessment. However, the fund is trading at a significant discount to its intrinsic value of $17.01 and offers a robust 10.03% dividend yield with a sustainable payout ratio. While long-term price performance is strong, the current technical trend is sharply bearish (10/100), suggesting a period of consolidation or decline despite the valuation gap.
Compare Another Pair
Related Comparisons
JPM vs NMAI: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Nuveen Multi-Asset Income Fund (NMAI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.